- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02245009
Safety of External Electrocardioversion in Device Patients (SEED)
Safety of External Electrocardioversion in Device Patients - the SEED Registry
Arrhythmias of the atria of the heart are a common comorbidity in patients with cardiac rhythm management devices, such as pacemakers and implantable cardioverter/defibrillators (ICD). External electrical cardioversion is an established method to achieve rhythm control (restore normal sinus rhythm) in patients with atrial arrhythmia. Little data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.
The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices.
Studie Overzicht
Gedetailleerde beschrijving
Introduction Atrial arrhythmias are a common comorbidity in patients with cardiac rhythm management (CRM) devices, such as pacemakers and ICD. External electrical cardioversion is an established method to achieve rhythm control in patients with atrial arrhythmia. A paucity of data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Most publications are of older date and predominantly case reports or case collections. Few prospective studies with a population of cardiac rhythm management patients after external electrical cardioversion have been published in recent years.
Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.
Rationale Electrocardioversion in Propofol sedation for atrial or ventricular tachyarrhythmia is an established therapy. It is routinely used for patients with cardiac rhythm management devices and the risk of device and lead affectation is deemed to be low. This assumption is currently not supported by substantial and current scientific data, mostly relying on older reports. No large, prospective trials with a population of patients with modern cardiac rhythm management devices exists.
Aim of the study The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices. Thereby, providing reliable evidence and detecting possible SAE with a low incidence. Furthermore, to gather information on efficacy and recurrence rate in this population, to examine the value of external electrical cardioversion for rhythm control in these patients.
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
-
Cologne, Duitsland, 50937
- Werving
- University Hospital Cologne
-
Contact:
- Daniel Steven, Prof. Dr.
- Telefoonnummer: 32396 +49221478
- E-mail: daniel.steven@uk-koeln.de
-
Hoofdonderzoeker:
- Jakob Lüker, Dr.
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Age ≥ 18 years
- Informed, written consent
- Atrial or ventricular arrhythmia with indication for CV
- Status post CRM implantation, including CRT-D
Exclusion Criteria:
- Age < 18 years
- Patients under guardianship or with mental disorders / disabilities
- lead implantation < 4 weeks prior to CV
- contraindications for eCV or transoesophageal echocardiographie (TOE)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Cohort
- Tijdsperspectieven: Prospectief
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Pacemaker patients
Patients with pacemaker, presenting for cardioversion.
|
|
|
ICD patients
Patients with ICD, presenting for cardioversion.
|
|
|
CRT patients
Patients with CRT device, presenting for cardioversion.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Composite safety endpoint: Changes of lead and device parameters
Tijdsspanne: 2 weeks after CV
|
assessed by device interrogation, if any of the following criteria is met:
|
2 weeks after CV
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Efficacy Endpoint
Tijdsspanne: within 15 minutes after CV
|
Assessed by device interrogation and 12-lead ECG: - restoration of normal sinus rhythm after CV |
within 15 minutes after CV
|
|
Late changes of lead parameters
Tijdsspanne: 2 weeks after CV
|
Any of the below, assessed by device interrogation:
|
2 weeks after CV
|
|
Inadvertent induction of ventricular fibrillation
Tijdsspanne: 10 seconds after CV
|
Assessed by 3 lead monitoring ECG
|
10 seconds after CV
|
|
Composite endpoint: Early lead changes
Tijdsspanne: within 15 minutes after CV
|
assessed by device interrogation, if any of the following criteria is met:
|
within 15 minutes after CV
|
|
Loss of programming
Tijdsspanne: within 15 minutes after CV
|
assessed by device interrogation: - loss of programming of the device |
within 15 minutes after CV
|
|
Change of shock impedance
Tijdsspanne: within 15 minutes after CV
|
assessed by device interrogation: - rise in shock impedance by 50% |
within 15 minutes after CV
|
|
Change of charge time
Tijdsspanne: within 15 minutes after CV
|
assessed by device interrogation: - rise in charge time by 50% |
within 15 minutes after CV
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Jakob Lüker, Dr., University Hospital Cologne
- Studie directeur: Daniel Steven, Prof. Dr., University Hospital Cologne
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- UKK-SEED-2014
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .